{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:09:33Z","timestamp":1779898173320,"version":"3.53.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Broad genomic profiling (BGP) is recommended for several types of metastatic cancer but remains underused. Over half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), where cost-containment strategies may limit access to BGP. Whether Medicare payer type and geographic region are associated with BGP use is not well established.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate whether BGP use differs by Medicare payer type (MA vs fee-for-service Medicare [FFS]) and to characterize geographic variation in BGP use across hospital referral regions (HRRs).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nationwide retrospective cohort study used Medicare Chronic Conditions Data Warehouse claims and service records to identify beneficiaries aged 66 years or older with a new diagnosis of metastatic cancer, including bladder, breast, colorectal, endometrial, kidney, lung, melanoma, pancreatic, prostate, or thyroid, from January 1, 2020, to June 30, 2022. Data analysis was conducted from October 2024 to March 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Medicare type (FFS vs MA) and HRR.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was receipt of BGP within 2 months before through 6 months after diagnosis. Mixed-effects logistic regression models were used to estimate adjusted odds ratios (AORs) for the association between Medicare type and BGP use, controlling for demographic, clinical, and geographic factors. HRR-level variation was summarized using the median odds ratio (MOR). Subgroup analyses stratified cancers by the strength of guideline recommendations for BGP.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 254\u202f720 Medicare beneficiaries with metastatic cancer (median age, 74 years [IQR, 70-79 years]; 141\u202f964 female [55.7%]), 112\u202f637 (44.2%) were enrolled in MA and 142\u202f083 (55.8%) in FFS. Overall, 64\u202f351 (25.3%) received BGP. FFS beneficiaries had higher BGP use than MA beneficiaries (36\u202f633 of 142\u202f083 [25.8%] vs 27\u202f718 of 112\u202f637 [24.6%]; AOR, 1.08 [95% CI, 1.06-1.10]). BGP use was more frequent among FFS vs MA beneficiaries for cancers with equivocal BGP recommendations (AOR, 1.15 [95% CI, 1.11-1.19]) and, to a lesser extent, cancers with explicit recommendations (AOR, 1.04 [95% CI, 1.02-1.07]). Adjusted BGP use varied widely across HRRs (range, 13.8%-35.9%; median, 24.5% [IQR, 21.8%-27.6%]; MOR, 1.28 [95% CI, 1.25-1.31]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of Medicare beneficiaries with metastatic cancer, BGP use differed by Medicare payer type and showed substantial regional variation. These findings highlight opportunities to improve guideline-concordant molecular testing.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.14919","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:32Z","timestamp":1779895832000},"page":"e2614919","source":"Crossref","is-referenced-by-count":0,"title":["Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Ryan D.","family":"Chow","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rothen","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Long","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela R.","family":"Soulos","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"},{"name":"Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangge","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kunst","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"},{"name":"Centre for Health Economics, University of York, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela A.","family":"Dinan","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"},{"name":"Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"},{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"8","key":"zoi260430r1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century.","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"zoi260430r4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaoncol.2025.0499","article-title":"Adoption of broad genomic profiling in patients with cancer.","volume":"11","author":"Wang","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi260430r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.38219","article-title":"Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare national coverage determination.","volume":"4","author":"Sheinson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi260430r6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7291","author":"Chase","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"7","key":"zoi260430r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.19963","article-title":"Biomarker testing approaches, treatment selection, and cost of care among adults with advanced cancer.","volume":"8","author":"DaCosta Byfield","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260430r8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jmoldx.2024.01.005","article-title":"Next-generation sequencing trends among adult patients with select advanced tumor types: a real-world evidence evaluation.","volume":"26","author":"Ferreira-Gonzalez","year":"2024","journal-title":"J Mol Diagn"},{"key":"zoi260430r9","doi-asserted-by":"publisher","author":"Caplan","journal-title":"JCO Precis Oncol","DOI":"10.1200\/PO.20.00422"},{"issue":"5","key":"zoi260430r10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jval.2020.01.018","article-title":"Insights from a temporal assessment of increases in US private payer coverage of tumor sequencing from 2015 to 2019.","volume":"23","author":"Trosman","year":"2020","journal-title":"Value Health"},{"issue":"6","key":"zoi260430r12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1377\/hlthaff.2020.02149","article-title":"Comparing Medicare Advantage and traditional Medicare: a systematic review.","volume":"40","author":"Agarwal","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi260430r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.34707","article-title":"Resource use and care quality differences among Medicare beneficiaries undergoing chemotherapy.","volume":"7","author":"Kalidindi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi260430r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2935","article-title":"Comparison of low-value services among Medicare Advantage and traditional Medicare beneficiaries.","volume":"3","author":"Boudreau","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"3","key":"zoi260430r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1762","article-title":"Trends in use of low-value care in traditional fee-for-service Medicare and Medicare Advantage.","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"20","key":"zoi260430r16","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1200\/JCO-24-01907","article-title":"Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare.","volume":"43","year":"2025","journal-title":"J Clin Oncol"},{"key":"zoi260430r17","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006819","article-title":"Comparison of cancer care delivery and outcomes in Medicare Advantage with traditional Medicare.","author":"Waheed","journal-title":"Ann Surg"},{"issue":"8","key":"zoi260430r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2826","article-title":"Association of Medicare Advantage premiums with measures of quality and patient experience.","volume":"3","author":"Haviland","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zoi260430r19","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14255","article-title":"Measuring restrictiveness of Medicare Advantage networks: a claims-based approach.","volume":"59","author":"Feyman","year":"2024","journal-title":"Health Serv Res"},{"issue":"6","key":"zoi260430r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0793","article-title":"Association of Medicare Advantage star ratings with racial, ethnic, and socioeconomic disparities in quality of care.","volume":"2","author":"Meyers","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"24","key":"zoi260430r21","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMsa1407273","article-title":"Racial and ethnic disparities among enrollees in Medicare Advantage plans.","volume":"371","author":"Ayanian","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi260430r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.42633","article-title":"Evaluation of low-value services across major Medicare Advantage insurers and traditional Medicare.","volume":"7","author":"Duggan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260430r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077797","article-title":"Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage.","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"zoi260430r24","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.37765\/ajmc.2024.89519","article-title":"The extent and growth of prior authorization in Medicare Advantage.","volume":"30","author":"Neprash","year":"2024","journal-title":"Am J Manag Care"},{"issue":"7","key":"zoi260430r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.1816","article-title":"Physician network breadth and plan quality ratings in Medicare Advantage.","volume":"2","author":"Sen","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"6","key":"zoi260430r26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.21.01359","article-title":"Medicare Advantage: a disadvantage for complex cancer surgery patients.","volume":"41","author":"Raoof","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi260430r27","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.37765\/ajmc.2021.88766","article-title":"Comparison of the use of the top-ranked cancer hospitals between Medicare Advantage and traditional Medicare.","volume":"27","author":"Kim","year":"2021","journal-title":"Am J Manag Care"},{"issue":"1","key":"zoi260430r28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi260430r29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2016.20324","article-title":"Trends and patterns of disparities in cancer mortality among US counties, 1980-2014.","volume":"317","author":"Mokdad","year":"2017","journal-title":"JAMA"},{"key":"zoi260430r30","doi-asserted-by":"publisher","DOI":"10.5888\/pcd21.240046","article-title":"Geospatial hot spots and cold spots in US cancer disparities and associated risk factors, 2004-2008 to 2014-2018.","volume":"21","author":"Guo","year":"2024","journal-title":"Prev Chronic Dis"},{"key":"zoi260430r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.puhe.2024.08.021","article-title":"Cancer mortality and geographic inequalities: a detailed descriptive and spatial analysis of social determinants across US counties, 2018-2021.","volume":"237","author":"Karadzhov","year":"2024","journal-title":"Public Health"},{"issue":"3","key":"zoi260430r32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaoncol.2021.7337","article-title":"Geospatial disparities in the treatment of curable breast cancer across the US.","volume":"8","author":"Hassett","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260430r33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamaoncol.2020.6086","article-title":"Regional adoption of commercial gene expression testing for prostate cancer.","volume":"7","author":"Leapman","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260430r35","first-page":"27","article-title":"More accurate racial and ethnic codes for Medicare administrative data.","volume":"29","author":"Eicheldinger","year":"2008","journal-title":"Health Care Financ Rev"},{"issue":"6","key":"zoi260430r36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"issue":"7","key":"zoi260430r37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2, pt 1","key":"zoi260430r39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1475-6773.2012.01449.x","article-title":"Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery.","volume":"48","author":"Butler","year":"2013","journal-title":"Health Serv Res"},{"key":"zoi260430r40","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.W2.96","article-title":"Geography and the debate over Medicare reform.","volume":"21","author":"Wennberg","year":"2002","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi260430r41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jech.2004.029454","article-title":"A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena.","volume":"60","author":"Merlo","year":"2006","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"zoi260430r42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/aje\/kwi017","article-title":"Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression.","volume":"161","author":"Larsen","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi260430r43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cncr.23229","article-title":"Geographic access to cancer care in the U.S.","volume":"112","author":"Onega","year":"2008","journal-title":"Cancer"},{"issue":"16","key":"zoi260430r44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18743","article-title":"Study of practice patterns in NGS vs single gene testing, provider-identified barriers to biomarker testing and utilization of liquid biopsy across multiple hospital-based cancer centers.","volume":"41","author":"Simpson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi260430r45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23157","article-title":"Real-world findings from a multi-institutional quality study using CFIR to explore gaps, challenges, and opportunities around implementing precision medicine in community cancer settings.","volume":"43","author":"Terrell","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi260430r46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18741","article-title":"New insights on oncologist use of genomic testing.","volume":"41","author":"Smith","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260430r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.5785","article-title":"Claim denials for cancer-related next-generation sequencing in Medicare.","volume":"8","author":"Kang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260430r48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.6459","article-title":"Insurance barriers to next-generation sequencing testing in lung cancer\u2014when policy delays care.","author":"Choradia","journal-title":"JAMA Oncol"},{"key":"zoi260430r2","unstructured":"NCCN guidelines. National Comprehnsive Cancer Network. Accessed July 23, 2025. https:\/\/www.nccn.org\/guidelines\/nccn-guidelines"},{"key":"zoi260430r3","unstructured":"National Coverage Determination (NCD): next generation sequencing (NGS): 90.2. Centers for Medicare & Medicaid Services. Accessed March 10, 2026. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?NCDId=372"},{"key":"zoi260430r11","unstructured":"Medicare enrollment dashboard. Centers for Medicare & Medicaid Services. Accessed July 17, 2025. https:\/\/data.cms.gov\/tools\/medicare-enrollment-dashboard"},{"key":"zoi260430r34","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2018. Surveillance, Epidemiology, and End Results Program; National Cancer Institute. April 15, 2021. Accessed March 12, 2026. https:\/\/seer.cancer.gov\/csr\/1975_2018\/index.html"},{"key":"zoi260430r38","unstructured":"Rural-Urban Continuum Codes. Economic Research Service; U.S. Department of Agriculture. Accessed December 20, 2025. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849451\/chow_2026_oi_260430_1779136103.61679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:34Z","timestamp":1779895834000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.14919","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}